Intervacc has extended its five-year distribution agreement with Dechra Pharmaceuticals regarding the quark vaccine Stringvac by an additional two years. The extension will take effect in April 2026. Dechra launched the vaccine in the UK in 2022 and has since expanded to 12 countries, most recently Spain, Portugal and Slovenia. Intervacc will retain distribution in Scandinavia.